Guangzhou Huateng Biomedical Technology

Guangzhou Huateng Biomedical Technology Co., Ltd. operates as a preclinical contract research organization (CRO), providing comprehensive services for the biopharmaceutical and medical device industries. The company was established in 2019 and secured angel round investment in the same year. A significant milestone was achieved when it became a results-oriented enterprise of South China University of Technology, with shareholdings from the China-Singapore International Joint Research Institute and the Guangzhou State-owned Assets Supervision and Administration Commission. Huateng has steadily grown, securing multiple funding rounds, including a Series A in 2022, a Series A+ in 2023, and a Series B in 2024.

The firm's core business revolves around providing animal models and outsourced preclinical R&D services. Its client base includes national scientific research institutions, hospitals, pharmaceutical companies, and medical device enterprises primarily in China but with a global reach across 10 countries. Revenue is generated by offering a suite of services, from developing disease-specific large animal models to conducting safety and efficacy evaluations for innovative drugs and medical devices. The company operates on a one-stop service model, aiming to support clients from the initial discovery phase through to regulatory submissions like IND applications.

Huateng's service portfolio is extensive, covering four main areas: Animal Models, Medical Device Testing, Preclinical Drug Development, and Laboratory Sciences. It has developed over 200 disease-specific large animal models, including miniature pigs, rabbits, and non-human primates, utilizing advanced technologies like CRISPR gene editing. For medical devices, it offers preclinical evaluation for a range of products such as structural heart devices and orthopedic materials, boasting a high success rate in complex surgical models. Drug development solutions include IND/IDE acceleration, ADME/PK profiling, and toxicology studies. The company is supported by significant infrastructure, including over 10,000 square meters of lab space and multiple research and breeding bases. It holds numerous qualifications, including AAALAC accreditation and OECD GLP compliance, underscoring its commitment to international standards.

Keywords: preclinical CRO, animal models, medical device testing, drug development, large animal models, GLP toxicology, safety evaluation, efficacy studies, biopharmaceutical services, translational research, gene editing models, IND enabling studies, surgical models, in vivo studies, preclinical research, biomedical research services, China life sciences, ISO 10993, AAALAC accredited, OECD GLP